New drug cocktail aims to fight Hard-to-Treat cancers
NCT ID NCT06320405
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This early-phase trial tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and effective for people with advanced or metastatic solid tumors. The study will enroll 38 adults whose cancer has spread or not responded to prior treatment. Researchers will monitor side effects and check if tumors shrink or stabilize.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axatilimab, retifanlimab, and paclitaxel
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced or metastatic solid tumors that have not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 38 participants, so results may not apply to everyone. The combination may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?